JP2020518276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518276A5 JP2020518276A5 JP2019561141A JP2019561141A JP2020518276A5 JP 2020518276 A5 JP2020518276 A5 JP 2020518276A5 JP 2019561141 A JP2019561141 A JP 2019561141A JP 2019561141 A JP2019561141 A JP 2019561141A JP 2020518276 A5 JP2020518276 A5 JP 2020518276A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- human
- nuclease
- nucleic acid
- engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 10
- 101710163270 Nuclease Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 230000002759 chromosomal effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022175346A JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762503060P | 2017-05-08 | 2017-05-08 | |
| US62/503,060 | 2017-05-08 | ||
| US201762579460P | 2017-10-31 | 2017-10-31 | |
| US62/579,460 | 2017-10-31 | ||
| PCT/US2018/031674 WO2018208837A1 (en) | 2017-05-08 | 2018-05-08 | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022175346A Division JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518276A JP2020518276A (ja) | 2020-06-25 |
| JP2020518276A5 true JP2020518276A5 (https=) | 2021-06-10 |
| JP7170666B2 JP7170666B2 (ja) | 2022-11-14 |
Family
ID=62555183
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019561141A Active JP7170666B2 (ja) | 2017-05-08 | 2018-05-08 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
| JP2022175346A Pending JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022175346A Pending JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10745665B2 (https=) |
| EP (2) | EP4029943A1 (https=) |
| JP (2) | JP7170666B2 (https=) |
| AU (1) | AU2018266698A1 (https=) |
| CA (1) | CA3062698A1 (https=) |
| WO (1) | WO2018208837A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018201144A1 (en) * | 2017-04-28 | 2018-11-01 | Precision Biosciences, Inc. | Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells |
| JP2020537515A (ja) | 2017-10-03 | 2020-12-24 | ジュノー セラピューティクス インコーポレイテッド | Ｈｐｖ特異的結合分子 |
| CA3094468A1 (en) * | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| WO2020112860A1 (en) * | 2018-11-30 | 2020-06-04 | Intima Bioscience, Inc. | Methods of identifying immunomodulatory genes |
| KR102691932B1 (ko) | 2019-04-03 | 2024-08-06 | 프리시젼 바이오사이언시스 인코포레이티드 | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 |
| US20220313737A1 (en) * | 2019-06-18 | 2022-10-06 | Celyad Oncology S.A. | Cd52-deficient cells for adoptive cell therapy |
| US12016883B2 (en) * | 2019-09-26 | 2024-06-25 | Nantbio, Inc. | Primary T-cell expansion |
| CN116134144A (zh) * | 2020-04-23 | 2023-05-16 | Az治疗股份有限公司 | 细胞的hla-i类mhc消融 |
| GB202006587D0 (en) * | 2020-05-04 | 2020-06-17 | Celyad S A | Improved scaffolds for multiplexed inhibitory rna |
| MX2023004811A (es) * | 2020-10-26 | 2023-06-29 | Res Institute At Nationwide Children´S Hospital | Células nk del receptor de antígeno quimérico (car) y usos de las mismas. |
| MX2023006878A (es) | 2020-12-11 | 2023-07-31 | Intellia Therapeutics Inc | Composiciones y métodos para reducir el mhc de clase ii en una célula. |
| CR20230320A (es) | 2020-12-23 | 2023-10-23 | Intellia Therapeutics Inc | Composiciones y métodos para reducir los hla-a en una célula |
| WO2022140587A1 (en) | 2020-12-23 | 2022-06-30 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying ciita in a cell |
| CN116848235A (zh) | 2020-12-30 | 2023-10-03 | 因特利亚治疗公司 | 工程化t细胞 |
| US20250127811A1 (en) | 2021-01-28 | 2025-04-24 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| EP4288525A1 (en) | 2021-02-08 | 2023-12-13 | Intellia Therapeutics, Inc. | Natural killer cell receptor 2b4 compositions and methods for immunotherapy |
| EP4288089A2 (en) | 2021-02-08 | 2023-12-13 | Intellia Therapeutics, Inc. | T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy |
| CN117042793A (zh) | 2021-02-08 | 2023-11-10 | 因特利亚治疗公司 | 用于免疫疗法的淋巴细胞活化基因3(lag3)组合物和方法 |
| EP4365203A4 (en) * | 2021-07-01 | 2025-09-24 | Ningbo T Maximum Biopharmaceuticals Co Ltd | ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND ITS APPLICATION |
| JP2024534114A (ja) | 2021-08-24 | 2024-09-18 | インテリア セラピューティクス，インコーポレイテッド | 細胞療法用のプログラム細胞死タンパク質１（ｐｄ１）組成物及び方法 |
| JP2024540723A (ja) | 2021-11-03 | 2024-11-01 | インテリア セラピューティクス，インコーポレーテッド | 免疫療法のためのｃｄ３８組成物及び方法 |
| AU2023293131A1 (en) | 2022-06-16 | 2024-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class i in a cell |
| WO2024006955A1 (en) | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
| WO2024186971A1 (en) | 2023-03-07 | 2024-09-12 | Intellia Therapeutics, Inc. | Cish compositions and methods for immunotherapy |
| WO2025038642A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying cd70 |
| IL326191A (en) | 2023-08-14 | 2026-03-01 | Intellia Therapeutics Inc | Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025137439A2 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Engineered t cells |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| DE69534629D1 (de) | 1994-01-18 | 2005-12-29 | Scripps Research Inst | Derivate von zinkfingerproteinen und methoden |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| USRE39229E1 (en) | 1994-08-20 | 2006-08-08 | Gendaq Limited | Binding proteins for recognition of DNA |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| WO2003087341A2 (en) | 2002-01-23 | 2003-10-23 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| WO2003080809A2 (en) | 2002-03-21 | 2003-10-02 | Sangamo Biosciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US20070134796A1 (en) | 2005-07-26 | 2007-06-14 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
| US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| ES2582091T3 (es) | 2005-10-18 | 2016-09-09 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| CA3111953C (en) | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| JP6681837B2 (ja) * | 2014-03-11 | 2020-04-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| US20170335331A1 (en) * | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| AU2016243583B2 (en) * | 2015-03-27 | 2022-03-10 | President And Fellows Of Harvard College | Modified T cells and methods of making and using the same |
| WO2016196388A1 (en) * | 2015-05-29 | 2016-12-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| JP6816133B2 (ja) * | 2015-10-05 | 2021-01-20 | プレシジョン バイオサイエンシズ，インク． | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| CA3009637A1 (en) * | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| JP2019509738A (ja) * | 2016-03-11 | 2019-04-11 | ブルーバード バイオ， インコーポレイテッド | ゲノム編集された免疫エフェクター細胞 |
-
2018
- 2018-05-08 EP EP21209275.3A patent/EP4029943A1/en active Pending
- 2018-05-08 AU AU2018266698A patent/AU2018266698A1/en not_active Abandoned
- 2018-05-08 EP EP18729846.8A patent/EP3634493A1/en not_active Withdrawn
- 2018-05-08 CA CA3062698A patent/CA3062698A1/en active Pending
- 2018-05-08 WO PCT/US2018/031674 patent/WO2018208837A1/en not_active Ceased
- 2018-05-08 JP JP2019561141A patent/JP7170666B2/ja active Active
-
2019
- 2019-11-08 US US16/678,600 patent/US10745665B2/en active Active
-
2020
- 2020-07-13 US US16/927,452 patent/US20200339952A1/en not_active Abandoned
-
2022
- 2022-04-04 US US17/712,864 patent/US20220228115A1/en active Pending
- 2022-11-01 JP JP2022175346A patent/JP2023022005A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518276A5 (https=) | ||
| Lei et al. | Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy | |
| JP7379447B2 (ja) | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 | |
| JP2023055884A5 (https=) | ||
| JP2025013884A5 (https=) | ||
| CN114736901B (zh) | 用于减少pd-l1表达的寡核苷酸 | |
| CN103343120B (zh) | 一种小麦基因组定点改造方法 | |
| JP2019522461A5 (https=) | ||
| JP2018534950A5 (https=) | ||
| JP2016538885A5 (https=) | ||
| CN112930395A (zh) | 靶向rna的融合蛋白组合物和使用方法 | |
| JP2021526858A5 (https=) | ||
| JP2022521486A5 (https=) | ||
| JP2018522072A5 (https=) | ||
| JP2011004753A5 (https=) | ||
| JP2010273685A5 (https=) | ||
| JP2013509168A5 (https=) | ||
| CN116083487A (zh) | 用于治疗遗传病状的方法和组合物 | |
| RU2013152648A (ru) | Аденовирус обезьян и гибридные аденовирусные векторы | |
| JP2019524140A5 (https=) | ||
| JP2017524348A5 (https=) | ||
| JP2022513586A (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| IL316189A (en) | Treatment of complement-mediated disorders | |
| AU2023347320A1 (en) | Compositions and methods for epigenetic regulation of hbv gene expression | |
| JP2020517270A5 (https=) |